Page last updated: 2024-09-04

cyc 202 and harmol

cyc 202 has been researched along with harmol in 2 studies

Compound Research Comparison

Studies
(cyc 202)
Trials
(cyc 202)
Recent Studies (post-2010)
(cyc 202)
Studies
(harmol)
Trials
(harmol)
Recent Studies (post-2010) (harmol)
979739383116

Protein Interaction Comparison

ProteinTaxonomycyc 202 (IC50)harmol (IC50)
rac GTPase-activating protein 1 isoform aHomo sapiens (human)44.91
Dual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)0.09
Serine/threonine-protein kinase haspinHomo sapiens (human)0.77
Dual specificity tyrosine-phosphorylation-regulated kinase 2Homo sapiens (human)1.5

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (50.00)29.6817
2010's1 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Deng, Y; Duan, J; Kesuma, D; Qi, RZ; Sim, MM; Song, Y; Teng, SF; Wang, J; Wang, JH1
Jarhad, DB; Jeong, LS; Kim, HR; Mashelkar, KK; Noh, M1

Reviews

1 review(s) available for cyc 202 and harmol

ArticleYear
Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase 1A (DYRK1A) Inhibitors as Potential Therapeutics.
    Journal of medicinal chemistry, 2018, 11-21, Volume: 61, Issue:22

    Topics: Animals; Biological Products; Disease; Dyrk Kinases; Enzyme Activation; Humans; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases

2018

Other Studies

1 other study(ies) available for cyc 202 and harmol

ArticleYear
Beta-carbolines as specific inhibitors of cyclin-dependent kinases.
    Bioorganic & medicinal chemistry letters, 2002, Apr-08, Volume: 12, Issue:7

    Topics: Carbolines; CDC2-CDC28 Kinases; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinase 5; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinases; Cyclins; Protein Serine-Threonine Kinases

2002